The Role of Sensor-Derived Daily Glycemic Variability in Treatment-Requiring Diabetic Ocular Disease: A Retrospective Case-Control Study.
文献摘要
Objective Daily glycemic variability (GV) has been proposed as a contributor to diabetic ocular complications beyond chronic glycemic management. This study evaluated whether sensor-derived GV (coefficient of variation, %CV) is associated with treatment-requiring diabetic ocular disease. Methods Retrospective case-control study of adults with diabetes followed by Endocrinology departments at 2 tertiary hospitals in Kingston, Ontario. Inclusion criteria were as follows: diabetes duration ≥5 years, age ≥18 years, continuous glucose monitoring (CGM) wear ≥70% in a continuous 90-day period (Jan 2023-May 2024), and a documented eye examination (Jan 2023-Dec 2024). Cases were identified as having received diabetic ocular treatment (intravitreal injection [IVI], retinal laser, and/or pars plana vitrectomy) using OHIP codes (2015-2024) and confirmed by blinded ophthalmology chart review; controls had not received such treatment. Device-reported 14- and 90-day CGM metrics were extracted. In cases treated between 2022 and 2024, IVI burden was compared by 90-day %CV (≤36 vs >36) and correlated with CGM metrics. Results Among 485 patients, 72 (14.8%) were cases. Cases were older and had a longer diabetes duration than controls (both p Conclusions Short-term CGM-derived GV was not associated with treatment-requiring diabetic ocular disease. Within recently treated patients, GV-treatment relationships likely reflect confounding by care intensity and disease stage.